Intellia Therapeutics Inc (FRA:38I)
€ 13.565 -0.175 (-1.27%) Market Cap: 1.44 Bil Enterprise Value: 903.64 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 57/100

Intellia Therapeutics Inc Launch of New Universal CAR-T Company with Cellex and Blackstone Life Sciences Corporate Call Transcript

Jun 22, 2021 / 12:00PM GMT
Release Date Price: €66.76 (+5.97%)
Operator

Good morning and welcome to Intellia Therapeutics Corporate Update Call. (Operator Instructions) Please be advised, this conference call is being recorded at the company's request.

I will now turn the conference over to Lina Li, Director of Investor Relations at Intellia. Please proceed.

Lina Li
Intellia Therapeutics, Inc. - Director of IR

Thank you, operator, and good morning, everyone.

Welcome to Intellia's corporate update call to discuss the establishment of a new universal CAR-T company. Earlier this morning, Intellia issued a joint press release with Blackstone Life Sciences and Cellex Cell Professionals detailing the terms of the venture. This release can be found on the Investors & Media section of Intellia's website at intelliatx.com. As a reminder, this call is being broadcast live and a replay will also be archived on the company's website.

Joining me on the call today are Dr. John Leonard, Chief Executive Officer; Dr. David Lebwohl, Chief Medical Officer; Dr. Laura Sepp-Lorenzino, Chief Scientific Officer; and Glenn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot